|Articles|April 15, 2002
PDT trials aim to extend knowledge from TAP, VIP studies
Baltimore-Ocular photodynamic therapy (PDT) using verteporfin (Visudyne, Novartis) already has been shown to be beneficial in the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
LASIK and beyond: Navigating the changing landscape of refractive surgery
2
What if? Ophthalmology without OCT – Part 5
3
Transformative advances in vision research: It’s the science
4
Q&A: James Chelnis discusses AAO 2025 presentation on aesthetic facial surgery
5













































.png)


